Uppsala Clinical Research Center

Slides:



Advertisements
Similar presentations
Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia ( TASTE trial) Ole Fröbert, MD, PhD - on behalf of the TASTE investigators Departement.
Advertisements

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents Christoph Varenhorst M.D Ph.D;
Stefan James, Uppsala University
on behalf of the TOTAL Investigators
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
SWEDE HEART Prospective Registry based Randomized Clinical Trials (RRCT) – a new concept for clinical research Lessons from the TASTE trial Stefan James,
ATTEMPT study: pooled-Analysis of Trials on ThrombEctomy in acute Myocardial infarction based on individual PatienT data CLINICAL TRIAL UPDATE III ESC.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
Improving outcome of STEMI PCI: Preliminary Results of Crystal AMI trial Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators.
EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
on behalf of the TOTAL Investigators
UNIVERSITÄT LEIPZIG H E R Z Z E N T R U M Infarct transmurality and infarct size assessed by delayed enhancement magnetic resonance imaging: Association.
For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2013 Medtronic, Inc. All rights reserved. UC ML.
Trial Vignettes 1-3 Mark Mason Harefield Hospital Royal Brompton and Harefield NHS Trust.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
The MASTER Trial A Prospective, Randomized, Multicenter Evaluation of a PET Micronet Mesh Covered Stent (MGuard) in STEMI Sigmund Silber, MD, PhD FESC,
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Issued in 2015 – SCAAR. SCAAR Annual report 2014.
Treatment of Thrombotic Lesions Ramesh Daggubati, MD FACC FSCAI Director of Interventional Cardiology East Carolina University Greenville, NC USA.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Eptifibatide is Noninferior to Abciximab in Primary PCI – Results From the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) Axel Åkerblom,
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.
Comparison of drug-eluting stents in real-life clinical practice in Sweden: Insights from the SCAAR register. Goran K. Olivecrona 1, Elvin Kedhi 2, Elmir.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
iFR vs FFR-guided Coronary Intervention – iFR-SWEDEHEART
Jose M. de la Torre Hernández … in behalf of the 3D investigators
Rationale for TOTAL trial: randomized trial of routine aspiration ThrOmbecTomy with PCI vs. PCI ALone in patients with STEMI undergoing primary PCI Sanjit.
Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL) Stefan James Professor of Cardiology Uppsala Clinical.
A Clinical profile of patients enrolled in the Pakistan ACS registry
iFR vs FFR-guided Coronary Intervention – iFR-SWEDEHEART
Pretreatment with P2Y12 Receptor Antagonists Is Not Associated with Improved Clinical Outcomes in ST-Elevation Myocardial Infarction: A Report from.
Heparin Should be the First-line Therapy for Patients with ACS/AMI
The American College of Cardiology Presented by Dr. Adnan Kastrati
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
For the HORIZONS-AMI Investigators
The European Society of Cardiology Presented by Dr. Saman Rasoul
Improved Outcomes in Patients with Non-ST-Elevation Myocardial Infarction during 20 Years are Related to Implementation of Evidence-based Treatments –
Is There a Role for Aspiration in STEMI?
Thomas Stiermaier, MD; Suzanne de Waha, MD;
ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.
Statins Evaluation in Coronary procedUres and REvascularization
European Society of Cardiology 2003
How and why this study may change my practice ?
Figure 1 PCI strategies in patients with STEMI and multivessel disease
3-Year Clinical Outcomes From the RESOLUTE US Study
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
A Systematic Review and Meta-analysis of Randomized Trials of Manual Thrombectomy in ST elevation myocardial infarction Investigators: Ashraf Alazzoni,
Published in the European Heart Journal
TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES
American College of Cardiology Presented by Dr. Michel R. Le May
SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Michael.
Global Registry of Acute Coronary Events: GRACE
Mancini JG, et al. Am J Cardiol.
Long-term safety and efficacy of zotarolimus-eluting and sirolimus-eluting stents in routine clinical care patients 36-month follow-up in the SORT OUT.
Ischemic Postconditioning
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
16-year follow-up of the DANish Acute Myocardial Infarction 2 (DANAMI-2) trial PG Thranea, SD Kristensena, KKW Olesena, LS Mortensenb, HE Bøtkera, L.
Presentation transcript:

Uppsala Clinical Research Center UCR Uppsala Clinical Research Center Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia (TASTE trial) Main results at 30 days Ole Fröbert, MD, PhD - on behalf of the TASTE investigators Departement of Cardiology Örebro University Hospital Sweden

Background Intracoronary thrombus aspiration may reduce distal embolization and improve reperfusion No previous randomized trial on thrombus aspiration has been powered for hard endpoints Current ESC recommendation: class IIa with a level of evidence B

/ Swedish registry data TAPAS / Swedish registry data TA+PCI (N=3 666) PCI alone (N=16 417) HR (95% CI): 1.21 (1.08-1.35) Data 2005-2009 Vlaar, P.J. et al. The Lancet 2008; 371:1915-20 Fröbert, O. et al. Int J Cardiol. 2010; 145:572-3

Methods (1) All 29 Swedish, 1 Icelandic and 1 Danish PCI center Inclusion criteria STEMI and ability to provide oral consent <24 h symptoms correspondence between ECG and angio findings Exclusion criteria need for emergency CABG age <18 years previous randomization in TASTE 1:1 randomization to manual thrombus aspiration and PCI vs. PCI alone

Methods (2) Endorsed aspiration catheters Eliminate (Terumo), Export (Medtronic) and Pronto (Vascular Solutions) Anticoagulation and platelet inhibition according to current guideline recommendations Primary endpoint time to all-cause death at 30 days Secondary endpoints time to rehospitalization with reinfarction at 30 days time to stent thrombosis at 30 days

Methods (3) TASTE introduces the Registry-based Randomized Clinical Trial (RRCT) concept Online health quality registries (SCAAR and SWEDEHEART) serve as on-line platforms for: randomization case record forms follow-up

TASTE trial enrollment flow chart Enrolled in Denmark N=247 All patients with STEMI in Sweden and Iceland undergoing primary or rescue PCI. N=11 709 *) Enrolled in TASTE N=7259 Not enrolled N=4697 Erroneous enrollments N=15 Randomized in TASTE N=7244 No patients (0) were lost to follow-up of the primary endpoint! N=3621 assigned to thrombus aspiration N=3623 assigned to conventional PCI N=3399 underwent thrombus aspiration N=222 underwent conventional PCI N=3445 underwent conventional PCI N=178 underwent thrombus aspiration N=1162 underwent thrombus aspiration N=3535 underwent conventional PCI N=3621 were followed up N=3623 were followed up N=1162 were followed up N=3535 were followed up

TASTE and previous studies

Baseline clinical characteristics

Baseline procedural characteristics

Post randomization characteristics (1)

Post randomization characteristics (2)

All-cause mortality at 30 days HR 0.94 (0.72 - 1.22), P=0.63 Per protocol analysis based on actual treatment: HR 0.88 (0.66 - 1.17), P=0.38

Reinfarction at 30 days HR 0.61 (0.34 - 1.07), P=0.09 Per protocol analysis based on actual treatment: HR 0.67 (0.36 - 1.20), P=0.19

Additional results

p

TASTE vs. TAPAS

TASTE vs. TAPAS

Conclusions This large, prospective, registry-based randomized clinical trial showed: no reduction of mortality at 30 days no significant reduction of hospitalization for MI or of stent thrombosis at 30 days no reduction of other important clinical endpoints during hospitalization Our findings leave little role for manual thrombus aspiration as a routine adjunct to PCI in STEMI

Participating centers Steering committee Stefan K. James, MD, PhD (chair) Bo Lagerqvist, MD, PhD Göran K. Olivecrona, MD, PhD Michael Mæng, MD, PhD (DENMARK) Thórarinn Gudnason, MD, PhD (ICELAND) Ole Fröbert, MD, PhD (PI) Participating centers Karolinska Institutet, Södersjukhuset, Sweden. Karolinska Solna and Huddinge Hospitals, Sweden. Karolinska University Hospital, Sweden. Kristianstad Hospital, Sweden. Sahlgrenska University Hospital, Gothenburg, Sweden. Skövde Hospital, Sweden. Sunderby Hospital, Sweden. Sundsvall Hospital, Sweden. Trollhättan Hospital, Sweden. Umeå University Hospital, Sweden. Uppsala Clinical research center, Sweden. Västerås Hospital, Sweden. Örebro University Hospital, Sweden. Landspitali University Hospital, Reykjavik, Iceland. Aarhus University Hospital, Denmark. Borås Hospital, Sweden. Capio, S:t Görans Hospital, Sweden. Danderyd University Hospital, Sweden. Eskilstuna Hospital, Sweden. Falun Hospital, Sweden. Gävle Hospital, Sweden. Halmstad Hospital, Sweden. Helsingborg Hospital, Sweden. Jönköping Hospital, Sweden. Linköping University Hospital, Sweden. Lund University Hospital, Sweden. Malmö Hospital, Sweden. Kalmar Hospital, Sweden. Karlskrona Hospital, Sweden. Karlstad Hospital, Sweden.